BMO Capital Markets Cuts Five Prime Therapeutics (FPRX) Price Target to $60.00
Five Prime Therapeutics (NASDAQ:FPRX) had its price target decreased by BMO Capital Markets from $75.00 to $60.00 in a report released on Wednesday. BMO Capital Markets currently has an outperform rating on the biotechnology company’s stock.
FPRX has been the topic of several other reports. Zacks Investment Research lowered Five Prime Therapeutics from a hold rating to a sell rating in a report on Wednesday, February 14th. BidaskClub raised Five Prime Therapeutics from a sell rating to a hold rating in a report on Thursday, December 21st. ValuEngine lowered Five Prime Therapeutics from a hold rating to a sell rating in a report on Tuesday, November 7th. Finally, Nomura dropped their price objective on Five Prime Therapeutics from $94.00 to $25.00 and set a buy rating on the stock in a report on Wednesday. Three analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $47.20.
Shares of Five Prime Therapeutics (NASDAQ:FPRX) traded down $0.80 on Wednesday, reaching $19.80. The company’s stock had a trading volume of 681,089 shares, compared to its average volume of 624,125. Five Prime Therapeutics has a one year low of $17.01 and a one year high of $48.87. The firm has a market capitalization of $647.26, a price-to-earnings ratio of -4.49 and a beta of 3.33.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.